anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a liquid concentrated detergent composition containing each specific anionic surfactant and nonionic surfactant in a specific ratio, having a low stimulation to the human body, excellent in fluidity, solubility to water, cleaning power and safety to environment, and useful as a liquid detergent for the table ware. SOLUTION: This liquid concentrated detergent composition contains (A) an anionic surfactant consisting of a sulfonated compound (salt) of an unsaturated fatty acid ester of a polyalkylene glycol monomethyl ether of formula I [R1 is a 13-19C alkyl containing an unsaturated bond; AO is an oxyethylene, etc.; (m) is 3-30], (B) a nonionic surfactant such as a higher alkanolamine of formula II [R2 is a 9-17C alkyl, etc.; (n) is 1, 2], a polyoxylakylene glycol alkyl ether of formula III [R3 is an 8-18C alkyl, etc.; BO is an oxyalkylene; (p) is (m)] and a fatty acid ester of a polyalkylene glycol of formula IV [R4 is a 5-17C alkyl, etc.; R5 is H or a 1-4C alkyl; DO is BO; (q) is (m)], with the weight ratio of the component A to B as the components A/B=(80/20)-(15/80), and the total concentration of the components is made as 55-100wt.%.
Methotrexate (MTX) is one of the first-line drugs used for the treatment of moderate to severe psoriasis. However, low bioavailability and systemic side effects of traditional oral and injectable MTX greatly limit its clinical application. Delivering MTX using dissolving microneedles (MNs) into psoriasis-like skin lesion could improve the in situ therapeutic effects with higher bioavailability and less side effects. Here, we propose a novel therapeutic approach for psoriasis involving MN-assisted percutaneous delivery of chitosan-coated hollow mesoporous silica nanoparticles containing MTX (MTX@HMSN/CS). The MTX@HMSN/CS-loaded MNs were strong enough to successfully penetrate the psoriasiform thickened epidermis, allowing MTX@HMSN/CS to be accurately delivered to the site of skin lesion following the rapid dissolution of MNs. MTX was then released continuously from HMSN/CS for at least one week to maintain effective therapeutic drug concentration for skin lesion with long-term anti-proliferative and anti-inflammatory effects. Incubation with MTX@HMSN/CS not only inhibited the proliferation of human immortalized keratinocytes (HaCaT cells), but also significantly reduced the expression of proinflammatory cytokines and chemokines. In addition, MTX@HMSN/CS-loaded MNs showed better efficacy in alleviating psoriasis-like skin inflammation than MTX-loaded MNs at the same dose. Compared to psoriasiform mice treated with 15.8 μg MTX-loaded MNs every day, 47.4 μg MTX@HMSN/CS-loaded MNs reduce the frequency of treatment to once every 3 days and achieve comparable amelioration. Therefore, MTX@HMSN/CS loaded MNs are a promising treatment strategy for psoriasis due to their durability, efficacy, convenience, and safety in relieving psoriasis-like skin inflammation.
A needle is inserted into the paravertebral space. After confirming the needle tip position, 20 ml of 0.5% ropivacaine is injected in the paravertebral space. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery.
OBJECTIVE: The aim of this study is to gain insight into the physical, psychological and social impact of having a myeloproliferative neoplasm (MPN), a rare type of cancer with an often chronic course.
METHODS: An online survey was conducted among 455 Dutch MPN patients (62.7% female, age M 63) to explore the impact of the disease by measuring the MPN symptom burden (MPN-SAF TSS) and quality of life (QoL) (EORTC QLQ-C30) and its subscales within a hierarchical QoL model. We examined differences in MPN symptom burden and QoL in relation to sociodemographic and disease-related factors. Hierarchical regression analysis was used to explain variances in QoL.
RESULTS: Most patients (97%) experienced MPN-related health complaints, with a significantly higher MPN symptom burden in women (M 31.50) compared to men (M 24.10). Regarding to fatigue and cognitive functioning MPN patients suffered more compared to a reference group of other cancers. MPN subtype or type of treatment did not show significant differences in MPN symptom burden or QoL. However, experiencing side effects, complications or comorbidities significantly negatively affected MPN symptom burden and QoL. 48.8% of patients reported that MPN affected their ability to work. The explained variance in overall QoL was 58%, most importantly by disease progression, comorbidities, MPN symptom burden and role, emotional and social functioning.
CONCLUSION: This study revealed that having an MPN has a negative impact on several domains of QoL. Symptom assessment and support should be included in the healthcare management of MPN patients.
FIELD: medicine, phytotherapy, sexology. SUBSTANCE: invention relates to the development of species prepared of the plant raw for increase of male potency. The species "Gusarsky" has 23 plants taken at the definite ratio and after oral intake it shows good clinical results. The species elicits tonic and sedative effect and recovers sexual potency. EFFECT: enhanced effectiveness of the species. 1 cl
Chronic Obstructive Pulmonary Disease (COPD) is an irreversible, progressive, treatable airway disease which causes dyspnea, wheezing, coughing and increased secretions in airways. Thoracic and respiratory mechanics are impaired, respiratory muscle strength and functional exercise capacity is decreased in patients with COPD. As a result dyspnea, limitation in activities of daily living, postural impairments, muscle length-strength relationship changes and increased mechanical loads on respiratory muscles occur. In literature it has been demonstrated that Kinesio Taping have therapeutic effects on respiratory functions and functional exercise capacity in patients with chronic neurological diseases who has additional respiratory impairments. Although there are several studies in literature investigating the effects of facilitation and inhibition taping techniques applied on respiratory muscles in patients with COPD, effects of thoracic and postural mechanical correction techniques as an alternative treatment modality in patients with COPD have not been investigated yet. In present study, effects of thoracic mechanical correction and facilitation taping techniques in patients with COPD will be investigated, and data will be collected for effects of thoracic mechanical correction taping on pulmonary parameters in patients with COPD.
PURPOSE: To obtain a medicine containing an inorganic phosphoric acid and adenosine and useful for increasing a total liver ATP(adenosine 5'-triphosphate) pool, a total blood ATP pool and a total blood plasma ATP level by administration to a host. CONSTITUTION: This medicine contains an inorganic phosphoric acid (e.g. sodium phosphate, potassium phosphate, phosphoric acid) and adenosine. The inorganic phosphoric acid is used in the form of an aqueous solution having a pH of 6.0-7.5, preferably 6.2-7.0, usually in an inorganic phosphoric acid/adenosine equivalent ratio of 1:>=1. The effective dose of the medicine is 1-1000mg/kg body/24hr on oral or topical administration, 0.01-500mg/kg body/24hr on injection, and 0.001-10mg/kg body/min on intravenous, intraabdominal or intra-arterial injection. An adenine nucleotide which is rapidly decomposed to produce the adenosine and the inorganic phosphoric acid after administration to a host may be used.
Patients will be initially treated with two cycles GELAD chemotherapy, followed by 50-56Gy radiotherapy, and completed with another two cycles GELAD chemotherapy. GELAD chemotherapy will be repeated every 21 days. Radiotherapy will be delivered in 25-32 fractions.
PURPOSE: The treatment of urethral stenosis after a combination of prostatectomy and radiation therapy for prostate cancer is understudied. We evaluate the clinical and patient-related outcomes after dorsal onlay buccal mucosal graft urethroplasty (D-BMGU) in men who underwent prostatectomy and radiation therapy.
MATERIALS AND METHODS: A multi-institutional, retrospective review of men with vesicourethral anastomotic stenosis or bulbomembranous urethral stricture disease after radical prostatectomy and radiation therapy from 8 institutions between 2013 to 2021 was performed. The primary outcomes were stenosis recurrence and development of de novo stress urinary incontinence. Secondary outcomes were surgical complications, changes in voiding, and patient-reported satisfaction.
RESULTS: Forty-five men were treated with D-BMGU for stenosis following prostatectomy and radiation. There was a total of 7 recurrences. Median follow-up in patients without recurrence was 21 months (IQR 12-24). There were no incidents of de novo incontinence, 28 patients were incontinent pre- and postoperatively, and of the 6 patients managed with suprapubic catheter preoperatively, 4 were continent after repair. Following repair, men had significant improvement in postvoid residual, uroflow, International Prostate Symptom Score, and International Prostate Symptom Score quality-of-life domain. Overall satisfaction was +2 or better in 86.6% of men on the Global Response Assessment.
CONCLUSIONS: D-BMGU is a safe, feasible, and effective technique in patients with urethral stenosis after a combination of prostatectomy and radiation therapy. Although our findings suggest this technique may result in lower rates of de novo urinary incontinence compared to conventional urethral transection and excision techniques, head-to-head comparisons are needed.
OBJECTIVE: Accumulative evidence indicates a critical role of mitochondrial function in autism spectrum disorders (ASD), implying that ASD risk may be linked to mitochondrial dysfunction due to DNA (mtDNA) variations. Although a few studies have explored the association between mtDNA variations and ASD, the role of mtDNA in ASD is still unclear. Here, we aimed to investigate whether mitochondrial DNA haplogroups are associated with the risk of ASD.
METHOD: Two European cohorts and an Ashkenazi Jewish (AJ) cohort were analyzed, including 2,062 ASD patients in comparison with 4,632 healthy controls. DNA samples were genotyped using Illumina HumanHap550/610 and Illumina 1M arrays, inclusive of mitochondrial markers. Mitochondrial DNA (mtDNA) haplogroups were identified from genotyping data using HaploGrep2. A mitochondrial genome imputation pipeline was established to detect mtDNA variants. We conducted a case-control study to investigate potential associations of mtDNA haplogroups and variants with the susceptibility to ASD.
RESULTS: We observed that the ancient adaptive mtDNA haplogroup K was significantly associated with decreased risk of ASD by the investigation of 2 European cohorts including a total of 2,006 cases and 4,435 controls (odds ratio = 0.64, P=1.79 × 10-5), and we replicated this association in an Ashkenazi Jewish (AJ) cohort including 56 cases and 197 controls (odds ratio = 0.35, P = 9.46 × 10-3). Moreover, we demonstrate that the mtDNA variants rs28358571, rs28358584, and rs28358280 are significantly associated with ASD risk. Further expression quantitative trait loci (eQTLs) analysis indicated that the rs28358584 and rs28358280 genotypes are associated with expression levels of nearby genes in brain tissues, suggesting those mtDNA variants may confer risk for ASD via regulation of expression levels of genes encoded by the mitochondrial genome.
CONCLUSION: This study helps to shed light on the contribution of mitochondria in ASD and provides new insights into the genetic mechanism underlying ASD, suggesting the potential involvement of mtDNA-encoded proteins in the development of ASD.
PLAIN LANGUAGE SUMMARY: Increasing evidence indicates that mitochondrial dysfunction may be linked to autism spectrum disorder (ASD). This study investigated potential associations of mitochondrial DNA (mtDNA) variants in 2 European and Ashkenazi Jewish cohorts including 2,062 individuals with ASD and 4,632 healthy controls. Researchers found that the ancient mtDNA haplogroup K was linked to a reduced risk of ASD in both European and Ashkenazi Jewish populations. Additionally, specific mtDNA variants were associated with ASD risk and were shown to influence the expression of nearby genes in the brain. These findings highlight the potential involvement of mtDNA in ASD development, offering new insights into the genetic mechanisms underlying the disorder.
Respiratory depression is the chief hazard of fentanyl transdermal system. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death.

Fentanyl transdermal system has a narrow indication and should be prescribed only by healthcare professionals who are knowledgeable in the administration of potent opioids and management of chronic pain [see Indications and Usage (1)]. Fentanyl transdermal system is contraindicated for use in conditions in which the risk of life threatening respiratory depression is significantly increased, including use as an as-needed analgesic, use in non-opioid tolerant patients, acute pain, and postoperative pain [see Contraindications (4)]. Proper dosing and titration of fentanyl transdermal system are essential [see Dosage and Administration (2.3)]. Overestimating the fentanyl transdermal system dose when converting patients from another opioid medication, can result in fatal overdose with the first dose. However, respiratory depression has also been reported with use of fentanyl transdermal system in patients who are opioid-tolerant, even when fentanyl transdermal system has been used as recommended and not misused or abused.

The mean half-life of fentanyl when delivered by fentanyl transdermal system is approximately 20 to 27 hours. Serum fentanyl concentrations continue to rise for the first two system applications. In addition, significant amounts of fentanyl continue to be absorbed from the skin for 24 hours or more after the patch is removed [see Clinical Pharmacology (12.3)].

Respiratory depression from opioids is manifested by a reduced urge to breathe and a decreased rate of respiration, often associated with a “sighing” pattern of breathing (deep breaths separated by abnormally long pauses). Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life threatening or fatal respiratory depression can occur at any time during the use of fentanyl transdermal system, the potential for serious, life threatening, or fatal respiratory depression is greatest during the first two applications following initiation of dosing, or following an increase in dosage. Closely monitor patients for respiratory depression when initiating therapy with fentanyl transdermal system, especially within the initial 24 to 72 hours when serum concentrations from the initial patch will peak, and following increases in dosage. Because significant amounts of fentanyl continue to be absorbed from the skin for 24 hours or more after the patch is removed, respiratory depression may persist beyond the removal of fentanyl transdermal system. Monitor patients for respiratory depression after patch removal to ensure that the patient’s respiration has stabilized for at least 24 to 72 hours or longer as clinical symptoms dictate.

Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status [see Overdose (10.2)].
The invention discloses a swine SAMHD1 gene. The sequence of the gene contains a nucleotide sequence coding an amino acid sequence represented by SEQIDNO.1. The invention also discloses a swine SAMHD2 protein. The amino acid sequence of the protein is represented by the SEQIDNO.1. The invention further discloses an anti-swine SAMHD1 protein monoclonal antibody. The swine SAMHD1 gene and the swine SAMHD1 protein have antiviral activity, are suitable for developing antiviral drugs, and have wide application prospect. The monoclonal antibody has very good specific response to the swine SAMHD1 protein, and lays a great foundation for developing the biological functions of the swine SAMHD1 protein.
NAC will be applied to 70 patients with birch pollen allergy. Subjects will initially receive a NAC with 0,9% saline solution to ensure negative reactivity to the challenge as method. If negative after 30 minutes NAC will continue with one puff (1x0.1 ml) dissolved ITULAZAX® (1 SQ-Bet/ml) in each nostril.
Patient with both PTSD and recent history of stroke. Methylphenidate active arm. The oral dosing maximum will be up to 20mg twice daily.
PURPOSE:A prolonged release type cefatrizine pharmaceutical, prepared by incorporating a cefatrizine pharmaceutical disintegrable in the stomach and enteric cefatrizine phamaceutical, having prolonged action on blood concentration without delay in the initial concentration by the oral administration, and useful as an antimicrobial agent. CONSTITUTION:A prolonged release type cefatrizine pharmaceutical prepared by incorporating (A) a cefatrizine pharmaceutical disintegrable in the stomach with (B) an enteric cefatrizine pharmceutical. The mixing potency ratio is preferably (30-50):(70-50). The cefatrizine pharmceutical disintegrable in the stomach (A) is preferably fine particles or granules disintegrable in the stomach, and the enteric cefatrizine pharmaceutical is preferably fine particles or granules obtained by coating the pharmaceutical disintegrable in the stomach (A) with an enteric film substance, e.g. ''Eudragit'' or carboxymethyl ethyl cellulose. The resultant pharmaceutical exhibits the blood concentration having the prolonged action without delay in the initial concentration by the oral administration.
Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.
The present invention relates to chemical formulas and preparation procedures of ten permanent gels to cover white spots on the skin caused by Vitiligo disease. The gels are cosmetic and allow concealing vitiligo stains indelibly for three to five days or more. The gels are made from natural ingredients with the purpose of not damaging the skin with vitiligo or cause allergies or irritation. Each gel gives a different tone to the skin with vitiligo, so they work for different skin tones, from white skin to dark skin. The fruits and seeds with which the gels were made contain pigments naturally. The fruits and seeds used in its production are Black Zapote, Walnut Paper, Black Tea, Black Pepper, Chinese Huizache, Purple Mesquite, and Aloe Vera. The permanent gels contain mashes of the mentioned fruits and seeds, as well as a Base Gel, elaborated with Carbopol, Glycerin and Triethanolamine, and Dilutions of Dihydroxyacetone and Citrus Acid.
For controlling the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age ≤ 35 years, COS will be carried out by daily injections of 150 IU of Human Menopausal Gonadotropins (HMG) and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the Gonadotropin-releasing Hormone (GnRH) antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary human Chorionic Gonadotropin (hCG) 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
This study is a multi-center, non-randomized, prospective single arm study with Type 1 patients with diabetes on insulin pump therapy with Continuous Glucose Monitoring (CGM). A total of up to 300 subjects age 18-80 will be enrolled at up to 20 investigational centers in the US. Each subject will wear their own MiniMed™ 670G insulin system. Each subject will be given 12 infusion sets to wear (each infusion set for at least 174 hours, or until infusion set failure if this occurs before 174 hours). Subjects will change insulin reservoirs at least every 174 hours. The time of infusion set insertion will be taken from Daily Log. Subjects can expect to participate for approximately 12-16 weeks.
The present invention relates to a method for extracting an extract from Phellinus linteus. Electrolyzed alkaline water having a small particle size through electrolysis is used by an extraction solvent for the Phellinus linteus. To prevent the destruction of active ingredients due to high-temperature water extraction, the ethanol and isopropanol are mixed for a low-temperature extraction operation for obtaining a beneficial Phellinus linteus extract. According to the present invention, the extraction method can be used to obtain the Phellinus linteus extract from Phellinus linteus powder by using the extraction solvent prepared by mixing weak alkaline water in pH 7.4-8.5, ethanol, and iso-propanol at the weight ratio of 20.5:10.5:10.5 at 60-70C for 4-6 hours. A method of using the extract from Phellinus linteus from Uzbekistan includes the process of obtaining the Phellinus linteus extract from Phellinus linteus powder by using the extraction solvent prepared by mixing weak alkaline water in pH 7.4-8.5, ethanol, and iso-propanol at the weight ratio of 20.5:10.5:10.5 at 60-70C for 4-6 hours. The Phellinus linteus extract is mixed with the aloe vera to alleviate atopic dermatitis, reduce skin irritation, and moisturize the skin.
In prospective and randomized trials, advance care planning (ACP) significantly improves outcomes including increased likelihood that clinicians and families understand and comply with a patient's wishes, reduces hospitalization at the end of life, results in less intensive treatments at the end of life (according to patients' wishes) and increases use of hospice services. Trials have not been done in primary care. The aim of this study is to determine the efficacy of a care pathway designed to increase the quality and quantity of ACP in patients and their substitute decision-makers in primary care. The study is a multi-site, patient-based, unblinded, randomized trial conducted in family practices in Canada. Participants will be patients who are determined by their physician to be able to benefit from ACP, and the patient's substitute decision-maker. Participant pairs will be randomized to immediate intervention (care pathway) or delayed (8-12 weeks). The intervention is guided use of tools and decision aids to clarify values and preferences for treatments in the event of serious illness or near end of life. The outcomes will be presence of a goals of care form in the chart, substitute decision-maker engagement in ACP (including self-efficacy for enacting the role), patient engagement in ACP, and decisional conflict.